Macrogenics, Inc. (MGNX)

$8.64

+0.16

(+1.89%)▲

Market is closed - opens 8 PM, 07 Dec 2023

Insights on Macrogenics, Inc.

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 71.17M → 10.39M (in $), with an average decrease of 44.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 57.46M → 17.55M (in $), with an average decrease of 69.5% per quarter

  • Vs SGEN

    In the last 1 year, Seagen, Inc. has given 80.8% return, outperforming this stock by 37.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 20.4% return, outperforming this stock by 83.1%

Performance

  • $8.51
    $8.79
    $8.64
    downward going graph

    1.5%

    Downside

    Day's Volatility :3.19%

    Upside

    1.71%

    downward going graph
  • $4.29
    $8.65
    $8.64
    downward going graph

    50.35%

    Downside

    52 Weeks Volatility :50.4%

    Upside

    0.12%

    downward going graph

Returns

PeriodMacrogenics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
63.64%
0.0%
0.0%
6 Months
64.57%
2.2%
0.0%
1 Year
43.05%
-4.7%
-2.1%
3 Years
-62.68%
18.0%
-6.5%

Highlights

Market Capitalization
519.8M
Book Value
$3.13
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
0.81
PE Ratio
10.35
PEG Ratio
0.01
Wall Street Target Price
12.11
Profit Margin
41.13%
Operating Margin TTM
-341.46%
Return On Assets TTM
-24.96%
Return On Equity TTM
31.44%
Revenue TTM
121.1M
Revenue Per Share TTM
1.96
Quarterly Revenue Growth YOY
-75.1%
Gross Profit TTM
-62.5M
EBITDA
-95.9M
Diluted Eps TTM
0.81
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.4
EPS Estimate Next Year
-1.87
EPS Estimate Current Quarter
-0.1
EPS Estimate Next Quarter
-0.52

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Macrogenics, Inc.(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
13
13
Hold
4
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 40.16%

Current $8.64
Target $12.11

Company Financials

FY17Y/Y Change
Revenue
155.5M
↑ 79.62%
Net Income
-19.6M
↓ 66.47%
Net Profit Margin
-12.62%
↑ 54.98%
FY18Y/Y Change
Revenue
60.1M
↓ 61.34%
Net Income
-171.5M
↑ 773.6%
Net Profit Margin
-285.18%
↓ 272.56%
FY19Y/Y Change
Revenue
62.0M
↑ 3.17%
Net Income
-151.8M
↓ 11.46%
Net Profit Margin
-244.76%
↑ 40.42%
FY20Y/Y Change
Revenue
97.8M
↑ 57.62%
Net Income
-117.8M
↓ 22.42%
Net Profit Margin
-120.48%
↑ 124.28%
FY21Y/Y Change
Revenue
75.6M
↓ 22.63%
Net Income
-190.9M
↑ 62.04%
Net Profit Margin
-252.31%
↓ 131.83%
FY22Y/Y Change
Revenue
151.9M
↑ 100.87%
Net Income
-120.0M
↓ 37.11%
Net Profit Margin
-78.99%
↑ 173.32%
Q2 FY22Q/Q Change
Revenue
26.0M
↑ 143.67%
Net Income
-40.8M
↓ 38.41%
Net Profit Margin
-156.88%
↑ 463.83%
Q3 FY22Q/Q Change
Revenue
41.7M
↑ 60.47%
Net Income
-24.7M
↓ 39.53%
Net Profit Margin
-59.11%
↑ 97.77%
Q4 FY22Q/Q Change
Revenue
71.2M
↑ 70.55%
Net Income
12.8M
↓ 151.89%
Net Profit Margin
17.99%
↑ 77.1%
Q1 FY23Q/Q Change
Revenue
24.2M
↓ 65.98%
Net Income
-38.2M
↓ 398.77%
Net Profit Margin
-157.96%
↓ 175.95%
Q2 FY23Q/Q Change
Revenue
13.1M
↓ 45.75%
Net Income
57.5M
↓ 250.25%
Net Profit Margin
437.49%
↑ 595.45%
Q3 FY23Q/Q Change
Revenue
10.4M
↓ 20.85%
Net Income
17.6M
↓ 69.45%
Net Profit Margin
168.84%
↓ 268.65%
FY17Y/Y Change
Total Assets
373.9M
↑ 20.12%
Total Liabilities
74.6M
↑ 75.59%
FY18Y/Y Change
Total Assets
332.1M
↓ 11.17%
Total Liabilities
89.3M
↑ 19.57%
FY19Y/Y Change
Total Assets
312.5M
↓ 5.91%
Total Liabilities
81.9M
↓ 8.27%
FY20Y/Y Change
Total Assets
378.7M
↑ 21.2%
Total Liabilities
82.9M
↑ 1.2%
FY21Y/Y Change
Total Assets
335.2M
↓ 11.48%
Total Liabilities
95.6M
↑ 15.41%
FY22Y/Y Change
Total Assets
280.5M
↓ 16.34%
Total Liabilities
138.5M
↑ 44.79%
Q2 FY22Q/Q Change
Total Assets
218.0M
↓ 19.67%
Total Liabilities
75.6M
↓ 18.95%
Q3 FY22Q/Q Change
Total Assets
195.3M
↓ 10.41%
Total Liabilities
72.4M
↓ 4.2%
Q4 FY22Q/Q Change
Total Assets
280.5M
↑ 43.57%
Total Liabilities
138.5M
↑ 91.27%
Q1 FY23Q/Q Change
Total Assets
343.5M
↑ 22.47%
Total Liabilities
234.2M
↑ 69.17%
Q2 FY23Q/Q Change
Total Assets
305.7M
↓ 11.02%
Total Liabilities
134.1M
↓ 42.74%
Q3 FY23Q/Q Change
Total Assets
340.0M
↑ 11.23%
Total Liabilities
146.0M
↑ 8.86%
FY17Y/Y Change
Operating Cash Flow
14.4M
↓ 132.98%
Investing Cash Flow
77.9M
↓ 210.86%
Financing Cash Flow
35.3M
↑ 1806.58%
FY18Y/Y Change
Operating Cash Flow
-153.2M
↓ 1163.76%
Investing Cash Flow
56.6M
↓ 27.26%
Financing Cash Flow
105.0M
↑ 197.02%
FY19Y/Y Change
Operating Cash Flow
-134.3M
↓ 12.38%
Investing Cash Flow
-79.4M
↓ 240.1%
Financing Cash Flow
120.0M
↑ 14.27%
FY20Y/Y Change
Operating Cash Flow
-111.9M
↓ 16.66%
Investing Cash Flow
-7.8M
↓ 90.19%
Financing Cash Flow
174.3M
↑ 45.32%
FY21Y/Y Change
Operating Cash Flow
-143.8M
↑ 28.54%
Investing Cash Flow
-36.6M
↑ 370.25%
Financing Cash Flow
122.8M
↓ 29.58%
FY22Y/Y Change
Operating Cash Flow
-87.0M
↓ 39.54%
Investing Cash Flow
70.7M
↓ 293.16%
Financing Cash Flow
1.7M
↓ 98.65%
Q2 FY22Q/Q Change
Operating Cash Flow
-49.2M
↓ 14.79%
Investing Cash Flow
23.0M
↓ 224.66%
Financing Cash Flow
263.0K
↑ 610.81%
Q3 FY22Q/Q Change
Operating Cash Flow
-9.4M
↓ 80.83%
Investing Cash Flow
71.9M
↑ 212.28%
Financing Cash Flow
1.4M
↑ 416.73%
Q4 FY22Q/Q Change
Operating Cash Flow
29.3M
↓ 411.19%
Investing Cash Flow
-5.8M
↓ 108.04%
Financing Cash Flow
1.4M
↑ 0.0%
Q1 FY23Q/Q Change
Operating Cash Flow
-12.8M
↓ 143.77%
Investing Cash Flow
28.1M
↓ 585.4%
Financing Cash Flow
100.1M
↑ 7267.03%
Q2 FY23Q/Q Change
Operating Cash Flow
-2.1M
↓ 83.72%
Investing Cash Flow
-113.5M
↓ 503.9%
Financing Cash Flow
59.0K
↓ 99.94%

Technicals Summary

Sell

Neutral

Buy

Macrogenics, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Macrogenics, Inc.
Macrogenics, Inc.
35.64%
64.57%
43.05%
-62.68%
-47.35%
Moderna, Inc.
Moderna, Inc.
9.42%
-35.83%
-54.97%
-49.47%
333.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.6%
13.15%
9.35%
68.7%
124.16%
Novo Nordisk A/s
Novo Nordisk A/s
-4.03%
23.9%
55.84%
186.15%
330.1%
Seagen, Inc.
Seagen, Inc.
0.86%
10.81%
80.8%
20.4%
259.73%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-6.55%
8.87%
11.3%
55.67%
105.25%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Macrogenics, Inc.
Macrogenics, Inc.
10.35
10.35
0.01
0.4
0.31
-0.25
0.0
3.13
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-12.72
-0.22
-0.07
0.0
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
23.18
23.18
1.75
42.5
0.17
0.09
0.01
234.47
Novo Nordisk A/s
Novo Nordisk A/s
41.18
41.18
4.02
2.67
0.89
0.22
0.01
20.77
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-4.16
-0.28
-0.13
0.03
13.52
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.38
26.38
0.5
15.04
0.23
0.14
0.0
64.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Macrogenics, Inc.
Macrogenics, Inc.
Buy
$519.8M
-47.35%
10.35
41.13%
Moderna, Inc.
Moderna, Inc.
Buy
$30.4B
333.33%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$88.5B
124.16%
23.18
30.47%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$459.0B
330.1%
41.18
35.11%
Seagen, Inc.
Seagen, Inc.
Hold
$40.2B
259.73%
NA
-32.61%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$90.5B
105.25%
26.38
35.94%

Institutional Holdings

  • Bellevue Group AG

    15.80%

  • BlackRock Inc

    9.73%

  • T. Rowe Price Investment Management,Inc.

    8.85%

  • Armistice Capital, LLC

    7.60%

  • Vanguard Group Inc

    7.12%

  • Millennium Management LLC

    3.29%

Company Information

a career at macrogenics could be waiting for you! please click on "careers" ---------------------------->>> to learn more. macrogenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. macrogenics creates both differentiated molecules that are directed to novel cancer targets, as well as “bio-betters,” which are drugs designed to improve upon marketed medicines. the combination of macrogenics’ technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. these are exciting times at macrogenics and we hope that you will take the opportunity to learn more about our organization, our pipeline and to view our job opportunities!

Organization
Macrogenics, Inc.
Employees
357
CEO
Dr. Scott Koenig M.D., Ph.D.
Industry
Health Technology

Discover More

FAQs